Pharmaceutical Companies
-
Africa CDC backs US$180M Biovac deal to end vaccine import dependence
The financing consortium includes Proparco, the European Investment Bank through the Human Development Accelerator initiative, and the International Finance Corporation.
-
Bristol Myers Squibb bets US$15.2B on Hengrui partnership to accelerate global drug pipeline
Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.
-
Novartis breaks ground on Texas’ first radioligand therapy site to secure U.S. cancer supply chain
The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.
-
GSK bets US$1B on SiranBio’s ALK7 siRNA to disrupt the obesity market
The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.
-
Eli Lilly invests US$4.5B more in Indiana manufacturing to increase production capacity
The additional funding will enhance two key facilities within the Lebanon complex, known collectively as the LEAP Research and Innovation District.
-
UCB expands autoimmune pipeline with US$2.2B Candid Therapeutics acquisition
The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.
-
Amgen boosts US biomanufacturing with additional US$300M investment in Puerto Rico
Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.
-
Merck completes US$6.7B acquisition of Terns Pharmaceuticals to strengthen the leukemia drug pipeline
Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.
-
Pharco Pharmaceuticals launches “Vision for All” to combat glaucoma in Egypt
The program focuses on early detection of eye diseases, with particular emphasis on glaucoma, while also supporting medical outreach through specialized convoys deployed in underserved communities.
-
Chiesi strengthens rare disease portfolio with US$1.9B acquisition of KalVista
Under the terms of the agreement, Chiesi will purchase KalVista for US$27 per share, representing a 36% premium over the company’s closing stock price on April 28.